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Abstract 
Background 
Recent outbreaks of Candida auris further exemplify that invasive Candida infections are a 
substantial threat to patients and health care systems. Even short treatment delays are associated 
with higher mortality rates. Epidemiological shifts towards more resistant Candida spp. require 
careful surveillance. 
Objectives 
Triggered by the emergence of C. auris and by increasing antifungal resistance rates the European 
Confederation of Medical Mycology developed an international Candida Registry (FungiScope™ 
CandiReg) to allow contemporary multinational surveillance. 
Methods 
CandiReg serves as platform for international cooperation to enhance research regarding invasive 
Candida infections. CandiReg uses the General Data Protection Regulation compliant data platform 
ClinicalSurveys.net that holds the electronic case report forms (eCRF). Data entry is supported via an 
interactive macro created by the software that can be accessed via any internet browser.  
Results 
CandiReg provides an eCRF for invasive Candida infections that can be used for a variety of studies 
from cohort studies on attributable mortality to evaluations of guideline adherence, offering to the 
investigators of the 28 ECMM member countries the opportunity to document their cases of invasive 
Candida infection. CandiReg allows the monitoring of epidemiology of invasive Candida infections, 
including monitoring of multinational outbreaks. Here, we describe the structure and management 
of the CandiReg platform. 
Conclusion 
CandiReg supports the collection of clinical information and isolates to improve the knowledge on 
epidemiology and eventually to improve management of invasive Candida infections. CandiReg 
promotes international collaboration, improving the availability and quality of evidence on invasive 
Candida infection and contributes to improved patient management.   
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Introduction 
Invasive Candida infections are among the most common bloodstream infections and are associated 
with high morbidity and mortality.1-3 Candida species are commensals of the human gastrointestinal 
microbiota and skin, but may translocate to the bloodstream and cause life-threatening infections. 
Invasive Candida infection (ICI) is an increasing threat to patients in the ICU, patients undergoing 
complicated or repeated gastrointestinal surgery and for immunocompromised patients, e.g., cancer 
patients, or recipients of solid organ or stem cell transplants.4 In some cases, dissemination 
complicates acute blood stream infection with deep tissue and organ involvement. Due to novel 
medical and immunological interventions and treatments, an increasing number of critically ill 
patients are at risk ICI. Common etiological agents are Candida albicans, Candida glabrata, Candida 
tropicalis, Candida parapsilosis and Pichia kudriavzevii (formerly Candida krusei) – depending on 
geographical region and patients’ risk groups. The emergence of C. auris, a novel, usually 
fluconazole-resistant and often multidrug-resistant Candida species has caused outbreaks worldwide 
and led to clinical alerts to U.S. and European healthcare facilities.5-8 In an Indian hospital C. auris has 
become the second most common cause of candidemia after C. tropicalis.9 The ECMM Candida 
Registry (CandiReg) was founded in January 2018, triggered by the recent C. auris candidemia 
outbreaks in Spain and the United Kingdom.10-12 
The main objective of CandiReg is to overcome the lack of knowledge on epidemiology, clinical 
course, and molecular characteristics of invasive Candida infections and to function as a platform for 
international multicenter studies and surveillance of multinational C. auris outbreaks. The specific 
objectives are to describe the incidence, to monitor trends globally and locally over time, to define 
patient risk groups, to assess antifungal resistance among Candida spp. causing invasive diseases 
worldwide, to assess attributable mortality and to assess to the cost augmentation associated with 
invasive Candida infection. A further goal of this platform is to set up a multinational collection of 
resistant Candida isolates with characterization at a molecular level, including the evaluation of 
resistance genes. 
We herein describe how FungiScope™ CandiReg is set up, maintained, and how it can be used to 
investigate the occurrence of ICI and potential outbreaks in future.  
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Methods 
CandiReg is an international non-interventional multicenter registry project. Treating physicians and 
medical microbiologists alike are invited to participate in the collection of clinical data and fungal 
isolates from cases of candidemia and tissue invasive candidiasis. The registry was founded in 
January 2018 and is ongoing without a defined endpoint. CandiReg uses an electronic case report 
form (eCRF) using the online electronic data capture platform www.clinicalsurveys.net (in 
cooperation with Questback GmbH, Cologne, Germany). The eCRF structure is modular and the 
system is programmed to adapt the eCRF by displaying or hiding items according to the documented 
case (e.g. candidemia vs. control patient). Case registration is on a voluntary basis. Target groups are 
patients with invasive candidiasis or candidemia. Export will be performed in SPSS-labelled data files 
in SPSS binary format. Statistical analyses will be performed with IBM SPSS Statistics software v.25.0 
(IBM Corp., Armonk, NY, USA/United States). 
 
Ethical and General Data Protection Regulation considerations 
CandiReg is approved by the local Institutional Review Board and Ethics Committee of the University 
Hospital Cologne (UHC) (Identifier of the University of Cologne Ethics Committee: 17-485). If needed, 
further local Ethics Committee approvals will be included. The study is registered at clinicaltrials.gov, 
identifier NCT03450005. CandiReg uses the General Data Protection Regulation (GDPR) compliant 
platform ClinicalSurveys.net. Data entry is carried out via any internet browser using encrypted 
communication. All documented data are automatically collected in a database. All Good 
Epidemiological Practice (GEP) requirements are met by the software. 
 
Results 
Case documentation and data collection 
Patients with candidemia or invasive candidiasis confirmed by culture, histopathology or microscopy 
can be included. A second cohort is defined by patients with signs of disseminated Candida infection 
without culture, histological or microscopical evidence (e.g. CT-imaging of target-lesions in liver and 
spleen and positive Candida antigen or Beta-D-Glucan tests in a neutropenic patient), so that chronic 
disseminated, culture negative candidiasis can be documented in an adjusted eCRF separable from 
patients with candidemia. Patients without evidence of invasive disease or those with colonization 
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only are not eligible. 
 
The following demographic data are collected: age group at the date of diagnosis, gender, year of 
infection, weight, ethnicity, details on primary underlying disease or conditions, 
immunosuppression, further risk factors, echocardiography and ophthalmology results, and 
mycological procedures allowing ICI diagnosis and sites of infection (Table 1). Details on 
management including antifungal treatment; recording drug, dose, duration, route of 
administration, therapeutic drug monitoring, reason for stopping, drug-related adverse events and 
surgical procedures, catheter management, clearance of bloodstream infection or infected sites are 
documented. Treatment indication is differentiated into prophylaxis, empiric, pre-emptive and 
targeted treatment for ambulatory and inpatient parenteral antifungal therapy. 
Response to antifungal therapy is evaluated after two and four weeks, three and six months and on 
the final day of observation. In addition, treatment response and outcome of the underlying disease 
as well as potential prolongation of hospital stay are also documented. Information on outcome 
includes overall mortality and attributable mortality. If available, autopsy results are recorded. 
Quality Management is covered once yearly from participating centers with regard to guideline 
implementation and adherence (ECIL, ESCMID, / ECMM, IDSA; EQUAL Candida Score, Infectious 
Diseases / Microbiology consulting services; Fellow of the ECMM availability, treatment in an ECMM 
Excellence Centre).13-18 Furthermore economic key figures and hospital characteristics with normal 
ward vs. ICU beds, candidemia per year, admissions per year, medical vs. surgical ward / ICU, 
consumption of antifungals in defined daily doses (DDD) are gathered. To implement health 
economic analyses on the incremental costs and attributable mortality analysis the study will in part 
use a matched case control design. Controls will be included from the same hospitals that include 
cases (i.e. one control per case, both from the same hospital). Controls will be matched by 
demographics, underlying diseases and risk factors as well as duration of hospitalization.19,20 
 
Isolates collection 
In addition to clinical data, partners can contribute with Candida isolates considered as emergent 
(e.g. Candida auris) for formal species identification and susceptibility testing. Isolates will be stored 
and made available to all collaborating partners for developing research projects. The following 
laboratory-based research will be conducted: isolate identification, macro-morphology, in vitro 
susceptibility testing according to EUCAST, evaluation and analysis of resistance mechanisms. 
Isolates are processed de-centrally at National Reference Centers or ECMM Excellence Centers, 
which serve as the central mycology reference laboratories.21,22 Species identification and 
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susceptibilities of all isolates are determined or confirmed using reference methods including mass 
spectrometry (MALDI- TOF MS/VITEK MS) and molecular methods (sequencing ITS, IGS or equivalent 
informative target). Mass- spectra and molecular data are analyzed using the MALDI- TOF libraries as 
well as sequencing databases such as MycoBank (http://www.mycobank.org/) and CBS-KNAW 
GenBank (http://www.westerdijkinstitute.nl/collections/). In addition, all isolates are stored in 
triplicate at −80°C for research exchange among CandiReg collaborators. Any such exchange is 
preceded by the contributor’s approval. The only exception from this self-rule is, if a contributor 
cannot be reached despite all efforts. Results of these analyses are also included in CandiReg, while 
the isolate remains stored in that reference laboratory. 
 
Case recruitment and data analyses and use 
The main variables to be analyzed are: clinical course and features of ICI, diagnostic procedures 
performed to confirm the diagnosis, description of antifungal treatment regimens, guideline 
implementation and adherence and their efficacy and impact on patient survival. The aim is to 
analyze the efficacy of current recommendations for diagnosis and treatment, to inform future 
consensus guidelines and to develop clinical screening and diagnostic procedures.  
 
Discussion and outlook 
CandiReg serves as platform for international cooperation and studies on attributable mortality, 
Candida-reactive T cells, evaluations of guideline adherence23-25, and recently the third multicenter 
ECMM study26,27 on incremental costs associated with nosocomial invasive candidiasis in Europe, 
CANDIDA III was initiated taking advantage of this platform. The CANDIDA III study focuses on 
evaluating the attributable mortality and costs as well as diagnostic and therapeutic approaches 
(including prolonged hospital stay for completion of parenteral antifungal treatment) of nosocomial 
invasive candidiasis in Europe. As a secondary objective, it will evaluate the antifungal resistance 
among Candida spp. causing invasive disease across Europe. The study will use a matched case 
control design, which will allow the implementation of health economic analysis on the incremental 
costs associated with invasive Candida infections. The ECMM will use the platform for future 
multinational surveillance studies on invasive candidemia in Europe. Moreover, investigators 
maintain familiarity with the platform, which may enable more rapid case entry in case of an 
outbreak. To date, 265 patients have been enrolled in the register as part of five open or completed 
studies.23-25,28 The results derived from this platform will be promoted as poster or oral presentations 
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at national and international infectious diseases, mycological and health-economic conferences. 
Internationally visible publications obtained from the CandiReg registry have already been published 
in or will be submitted to peer-reviewed journals. 
CandiReg will enhance knowledge about ICI and facilitate the analysis of epidemiological shifts and 
resistance trends. Currently, clinicians, microbiologists and researchers from 28 countries are 
involved (Figure 1). With this registry, we collect real life data with long-term observations. The 
registry will provide controlled or uncontrolled level II evidence and is ready in case of an outbreak 
situation similar to other FungiScope™ Registries.29 
There are a number of limitations of registry based studies. The retrospective acquisition of 
anonymized data of the individual patient reduces data quality, but is indispensable to protect 
privacy and comply with data protection guidelines. Also, the follow-up time of the cases may often 
be somewhat short. However, these registries offer the opportunity to contribute to progress in the 
understanding of epidemiology, pathophysiology, natural history and efficacy of treatments on a 
pan-European or even worldwide scale. As proven ICI is a relatively rare condition, pooling these 
cases and analyzing them in large cohorts can significantly improve our knowledge of ICI in real life 
settings and contribute to the design of clinical trials. Furthermore, they provide data unobtainable 
by controlled trials. 
In conclusion, the CandiReg platform promotes international collaboration, increases the quality of 
available evidence on invasive Candida infection and can contribute to improvement of patient 
management.23  
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Table 1. ECMM Candida Registry – Information categories captured 
Category Subcategory 
Demographics Age group at diagnosis, gender, year of infection, weight, ethnicity 
Host and risk factors Malignancy, SOT, HIV/AIDS, surgery trauma, burn, chronic diseases, 
autoimmune disease, alcoholism, iv drug use, ICU stay, neutropenia, 
obesity, premature birth, central venous catheters, foreign bodies, low 
albumin levels, extracorporeal membrane oxygenation (ECMO) 
Clinical presentation Signs and symptoms, site(s) of infection 
Diagnostics Mycological procedures for diagnosis of ICI. Echocardiography and 
ophthalmoscopy 
Treatment of IFD Prophylaxis, empiric and targeted therapy (antifungal drug, dose, duration, 
route of administration, reason for stopping, drug related adverse events, 
ambulatory parenteral antifungal treatment) surgical procedures, catheter 
management, clearance of Candida spp. from bloodstream or infected 
sites. 
Treatment response 
and outcome 
Response to antifungal treatment, outcome of ICI and underlying disease, 
prolongation of hospital stay 
Economics Hospital characteristics (normal ward / ICU beds; admissions per year), 
consumption of antifungals in defined daily doses (DDD) 
Quality  Guideline Implementation and Adherence (ECIL, ESCMID/ECMM, IDSA), 
EQUAL Candida Score, Infectious Diseases / Microbiology consulting 
services; Fellow of the ECMM available, ECMM Excellence Center 
 
AIDS= acquired immune deficiency syndrome; ECIL= European Conference on Infections in 
Leukaemia; ECMM= European Confederation of Medical Mycology; ESCMID= European Society of 
Clinical Microbiology and Infectious Diseases; HIV= human immunodeficiency virus; ICI= invasive 
Candida infection; ICU=intensive care unit; IDSA= Infectious Diseases Society of America; SOT=solid 
organ transplantation. 
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Figure 1. ECMM Member countries contributing to CandiReg, as of May 2019. The current 28 
member countries are colored in blue.  
